403 POSTER Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial

Solid Tumor ◽

Preliminary Report ◽

Kinase Inhibitor ◽

Standard Of Care ◽

Tumor Patients ◽

Clinical Responses ◽

Phase 1B ◽

Refractory Solid Tumor

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-013-2339-y ◽

2013 ◽

Vol 73 (1) ◽

pp. 181-189 ◽

Cited By ~ 55

Author(s):

Ana M. Molina ◽

Thomas E. Hutson ◽

James Larkin ◽

Anne M. Gold ◽

Karen Wood ◽

...

Keyword(s):

Clinical Trial ◽

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Phase 1B

Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma

Anti-Cancer Drugs ◽

10.1097/cad.0b013e3282fc6cf7 ◽

2008 ◽

Vol 19 (5) ◽

pp. 547-552 ◽

Cited By ~ 41

Author(s):

Sarah-Jane Dawson ◽

Nelly Marmy Conus ◽

Guy C. Toner ◽

Jeanette M. Raleigh ◽

Rodney J. Hicks ◽

...

Keyword(s):

Thyroid Carcinoma ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Clinical Responses

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

BMC Cancer ◽

10.1186/1471-2407-11-1 ◽

2011 ◽

Vol 11 (1) ◽

Cited By ~ 81

Author(s):

Satoshi Watanabe ◽

Junta Tanaka ◽

Takeshi Ota ◽

Rie Kondo ◽

Hiroshi Tanaka ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Lung Cancer Patients ◽

Clinical Responses

Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-2-s3-p230 ◽

2014 ◽

Vol 2 (Suppl 3) ◽

pp. P230 ◽

Author(s):

Mamun Majumder ◽

Ashwini Kumar ◽

Caroline Heckman ◽

Matti Kankainen ◽

Sari Pesonen ◽

...

Keyword(s):

Gene Expression ◽

Immune Response ◽

Expression Analysis ◽

Solid Tumor ◽

Gene Expression Analysis ◽

Tumor Patients ◽

Intratumoral Administration ◽

Refractory Solid Tumor

Can any patients with chronic myeloid leukemia outside of a clinical trial have their tyrosine kinase inhibitor discontinued?

Current Opinion in Hematology ◽

10.1097/moh.0000000000000321 ◽

2017 ◽

Vol 24 (2) ◽

pp. 125-131 ◽

Author(s):

Michael J. Mauro

Keyword(s):

Clinical Trial ◽

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor

Abstract B278: PR610: A novel hypoxia-selective tyrosine kinase inhibitor in phase I clinical trial.

10.1158/1535-7163.targ-13-b278 ◽

2013 ◽

Author(s):

Adam V. Patterson ◽

Jagdish Jaiswal ◽

Kendall Carlin ◽

Maria R. Abbattista ◽

Christopher P. Guise ◽

...

Keyword(s):

Clinical Trial ◽

Tyrosine Kinase ◽

Phase I ◽

Kinase Inhibitor ◽

Phase I Clinical Trial

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

PLoS ONE ◽

10.1371/journal.pone.0181782 ◽

2017 ◽

Vol 12 (7) ◽

pp. e0181782 ◽

Cited By ~ 16

Author(s):

Kathleen M. Gillooly ◽

Claudine Pulicicchio ◽

Mark A. Pattoli ◽

Lihong Cheng ◽

Stacey Skala ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Standard Of Care ◽

Experimental Models ◽

Bruton’S Tyrosine Kinase ◽

Bruton's Tyrosine Kinase

Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-05-2152 ◽

2006 ◽

Vol 12 (12) ◽

pp. 3782-3791 ◽

Cited By ~ 22

Author(s):

Larry J. Schaaf ◽

Lisa A. Hammond ◽

Stuart J. Tipping ◽

Richard M. Goldberg ◽

Rakesh Goel ◽

...

Keyword(s):

Pharmacokinetic Study ◽

Solid Tumor ◽

Hepatic Dysfunction ◽

Phase 1 ◽

Tumor Patients ◽

Refractory Solid Tumor

A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.608 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 608-608 ◽

Author(s):

Komal L. Jhaveri ◽

Erika Paige Hamilton ◽

Kathy Miller ◽

Maria Roche ◽

Mark S. Berger ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Tyrosine Kinase ◽

Blood Brain Barrier ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Brain Barrier ◽

Blood Brain ◽

Phase 1B

First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e14501 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e14501-e14501 ◽

Author(s):

Jeeyun Lee ◽

Seung Kim ◽

Sujin Lee ◽

Se Hoon Park ◽

Joon Oh Park ◽

...

Keyword(s):

Growth Factor ◽

Hepatocyte Growth Factor ◽

Phase I ◽

Solid Tumor ◽

Phase I Trial ◽

Tumor Patients ◽

Refractory Solid Tumor ◽

Hepatocyte Growth